McLean Susannah, Sheikh Aziz
Centre for Population Health Sciences: GP Section, Allergy and Respiratory Research Group, University of Edinburgh, Medical School, Edinburgh, United Kingdom.
Patient Prefer Adherence. 2010 May 13;4:69-76. doi: 10.2147/ppa.s4203.
Bacterial eye infections are commonly treated with topical antibiotics, despite limited evidence of effectiveness. Azithromycin 1% in DuraSite((R)) is a new formulation of azithromycin in a gel polymer designed for use in acute bacterial conjunctivitis.
We conducted systematic searches of the Cochrane Database of Clinical Trials, PubMed and Google Scholar to find randomized controlled trials of "azithromycin DuraSite((R))". These searches of published literature were supplemented with searches for unpublished trials and trials in progress.
We found six reports of randomized controlled trials investigating the role of azithromycin 1% in DuraSite((R)) for the management of acute bacterial conjunctivitis. The quality of these trials was judged to be moderate to high. These trials assessed effectiveness, tolerability and safety outcomes, but we found no trials looking at cost-effectiveness. DuraSite((R)) is a relatively stable formulation and so azithromycin 1% in DuraSite((R)) has a simpler dosing schedule than other available topical antibiotics. It appears to be similar to other topical antibiotics in its effectiveness, but minor side effects are quite common.
Acute bacterial conjunctivitis is a relatively mild, typically self-limiting, infection. Antibiotics should seldom be required. If, however, a decision to prescribe antibiotics is made, azithromycin 1% in DuraSite((R)) is likely to be broadly comparable in its effectiveness to most other antibiotics used to treat acute bacterial conjunctivitis. Further research is needed to determine its cost-effectiveness.
尽管有效性证据有限，但细菌性眼部感染通常仍用局部抗生素治疗。1% 阿奇霉素眼用凝胶（DuraSite((R))）是阿奇霉素的一种新型制剂，呈凝胶聚合物形式，用于治疗急性细菌性结膜炎。
我们对Cochrane临床试验数据库、PubMed和谷歌学术进行了系统检索，以查找 “阿奇霉素眼用凝胶（DuraSite((R))）” 的随机对照试验。对已发表文献的这些检索还补充了对未发表试验和正在进行的试验的检索。
我们发现了6篇关于1% 阿奇霉素眼用凝胶（DuraSite((R))）在急性细菌性结膜炎治疗中作用的随机对照试验报告。这些试验的质量被判定为中等至高。这些试验评估了有效性、耐受性和安全性结果，但我们未发现评估成本效益的试验。眼用凝胶（DuraSite((R))）是一种相对稳定的制剂，因此1% 阿奇霉素眼用凝胶（DuraSite((R))）的给药方案比其他可用的局部抗生素更简单。其有效性似乎与其他局部抗生素相似，但轻微副作用相当常见。
急性细菌性结膜炎是一种相对轻微、通常为自限性的感染。很少需要使用抗生素。然而，如果决定开抗生素，1% 阿奇霉素眼用凝胶（DuraSite((R))）在有效性方面可能与大多数其他用于治疗急性细菌性结膜炎的抗生素大致相当。需要进一步研究以确定其成本效益。
